inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all variant annotations for IKBKG

Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
No VIP available CA VA
rs1050828 NC_000023.10:g.153764217C>T, NC_000023.11:g.154536002C>T, NG_009015.2:g.16571G>A, NM_000402.4:c.292G>A, NM_001042351.2:c.202G>A, NP_000393.4:p.Val98Met, NP_001035810.1:p.Val68Met, NW_003871103.3:g.1969981C>T, XM_005274657.1:c.292G>A, XM_005274657.2:c.292G>A, XM_005274658.1:c.202G>A, XM_005274658.2:c.202G>A, XM_005277833.1:c.292G>A, XM_005277834.1:c.202G>A, XM_011531132.1:c.292G>A, XP_005274714.1:p.Val98Met, XP_005274715.1:p.Val68Met, XP_005277890.1:p.Val98Met, XP_005277891.1:p.Val68Met, XP_011529434.1:p.Val98Met, rs1894404, rs2230034, rs3191188
C > T
No VIP available No Clinical Annotations available VA
rs5030868 NC_000023.10:g.153762634G>A, NC_000023.11:g.154534419G>A, NG_009015.2:g.18154C>T, NM_000402.4:c.653C>T, NM_001042351.2:c.563C>T, NP_000393.4:p.Ser218Phe, NP_001035810.1:p.Ser188Phe, NW_003871103.3:g.1968398G>A, XM_005274657.1:c.656C>T, XM_005274657.2:c.656C>T, XM_005274658.1:c.566C>T, XM_005274658.2:c.566C>T, XM_005277833.1:c.656C>T, XM_005277834.1:c.566C>T, XM_011531132.1:c.656C>T, XP_005274714.1:p.Ser219Phe, XP_005274715.1:p.Ser189Phe, XP_005277890.1:p.Ser219Phe, XP_005277891.1:p.Ser189Phe, XP_011529434.1:p.Ser219Phe
G > A
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147


Alternate Names:  IP1; IP2
Alternate Symbols:  FIP-3; FIP3; Fip3p; IKK-gamma; NEMO; ZC2HC9
PharmGKB Accession Id: PA29777


Cytogenetic Location: chrX : q28 - q28
GP mRNA Boundary: chrX : 153769419 - 153796804
GP Gene Boundary: chrX : 153759419 - 153799804
Strand: plus


UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

PharmGKB contains no curated pathways for this gene. If you would like to volunteer to work on a pathway, please let us know.

External Pathways

Links to non-PharmGKB pathways.

  1. BCR signaling pathway - (Pathway Interaction Database NCI-Nature Curated)
  2. bone remodeling - (BioCarta via Pathway Interaction Database)
  3. Canonical NF-kappaB pathway - (Pathway Interaction Database NCI-Nature Curated)
  4. ceramide signaling pathway - (BioCarta via Pathway Interaction Database)
  5. chaperones modulate interferon signaling pathway - (BioCarta via Pathway Interaction Database)
  6. double stranded rna induced gene expression - (BioCarta via Pathway Interaction Database)
  7. Downstream TCR signaling - (Reactome via Pathway Interaction Database)
  8. IL1-mediated signaling events - (Pathway Interaction Database NCI-Nature Curated)
  9. inactivation of gsk3 by akt causes accumulation of b-catenin in alveolar macrophages - (BioCarta via Pathway Interaction Database)
  10. influence of ras and rho proteins on g1 to s transition - (BioCarta via Pathway Interaction Database)
  11. keratinocyte differentiation - (BioCarta via Pathway Interaction Database)
  12. nf-kb signaling pathway - (BioCarta via Pathway Interaction Database)
  13. nfkb activation by nontypeable hemophilus influenzae - (BioCarta via Pathway Interaction Database)
  14. p75(NTR)-mediated signaling - (Pathway Interaction Database NCI-Nature Curated)
  15. role of egf receptor transactivation by gpcrs in cardiac hypertrophy - (BioCarta via Pathway Interaction Database)
  16. signal transduction through il1r - (BioCarta via Pathway Interaction Database)
  17. TCR signaling in naïve CD4+ T cells - (Pathway Interaction Database NCI-Nature Curated)
  18. TCR signaling in naïve CD8+ T cells - (Pathway Interaction Database NCI-Nature Curated)
  19. TNF receptor signaling pathway - (Pathway Interaction Database NCI-Nature Curated)
  20. tnf/stress related signaling - (BioCarta via Pathway Interaction Database)
  21. toll-like receptor pathway - (BioCarta via Pathway Interaction Database)
  22. TRAF6 Mediated Induction of the antiviral cytokine IFN-alpha/beta cascade - (Reactome via Pathway Interaction Database)
  23. TRAIL signaling pathway - (Pathway Interaction Database NCI-Nature Curated)
  24. trefoil factors initiate mucosal healing - (BioCarta via Pathway Interaction Database)
  25. Viral dsRNA:TLR3:TRIF Complex Activates RIP1 - (Reactome via Pathway Interaction Database)

Curated Information ?

Evidence Gene
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available

Curated Information ?

Curated Information ?

Publications related to IKBKG: 3

No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals. Antimicrobial agents and chemotherapy. 2010. Shekalaghe Seif A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The impact of phenotypic and genotypic G6PD deficiency on risk of plasmodium vivax infection: a case-control study amongst Afghan refugees in Pakistan. PLoS medicine. 2010. Leslie Toby, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The NEMO mutation creating the most-upstream premature stop codon is hypomorphic because of a reinitiation of translation. American journal of human genetics. 2006. Puel Anne, et al. PubMed


Comparative Toxicogenomics Database:
HumanCyc Gene:

Common Searches